Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates

Dexamethasone (DEX) is the first drug to show life-saving efficacy in patients with severe coronavirus disease 2019 (COVID-19), while DEX is associated with serious adverse effects. Here, we report an inhaled, Self-immunoregulatory, Extracellular Nanovesicle-based Delivery (iSEND) system by engineer...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Qian-Fang, Tai, Wanbo, Tian, Mingyao, Zhuang, Xinyu, Pan, Yuanwei, Lai, Jialin, Xu, Yangtao, Xu, Zhiqiang, Li, Min, Zhao, Guangyu, Yu, Guang-Tao, Yu, Guocan, Chen, Rongchang, Jin, Ningyi, Li, Xiao, Cheng, Gong, Chen, Xiaoyuan, Rao, Lang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266725/
https://www.ncbi.nlm.nih.gov/pubmed/37315135
http://dx.doi.org/10.1126/sciadv.adg3277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266725/
https://www.ncbi.nlm.nih.gov/pubmed/37315135
http://dx.doi.org/10.1126/sciadv.adg3277

Ejemplares similares